• Azitra reported that its ATR-COSF cosmetic candidate reduced wrinkles and improved elasticity in two ex vivo human skin models.
• A single 2% dose reduced fine lines and wrinkles approximately 50% at 48 hours in dorsal skin samples.
• The treatment preserved elasticity over 48 hours; hydrogel alone showed declining elasticity and approximately 20% worsening in wrinkles.
• In face-lift skin samples, the 4% formulation improved all measured elasticity parameters at six hours, outperforming the 2% formulation and hydrogel.
• A first-in-human study of 4% ATR-COSF is planned in approximately 30 participants, with initial results expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048431), on October 26, 2026, and is solely responsible for the information contained therein.